BTIG on Verastem (VSTM): data supports drug's ~$1B peak sales potential

April 10, 2026 12:26 PM

BTIG analyst Jeet Mukherjee reiterated a Buy rating and $19.00 price target on Verastem (NASDAQ: VSTM)The analyst commented, "Two-year follow-up ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found